Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)

被引:0
|
作者
Swathi Lingam
Nopnithi Thonghin
Robert C. Ford
机构
[1] The University of Manchester,Faculty of Biology, Medicine and Health
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ivacaftor is a potentiator of the CFTR chloride channel and is in worldwide clinical use for the chronic treatment of cystic fibrosis in patients. There is evidence that the bioavailability of ivacaftor in the body may be influenced by the multi-drug exporter P-glycoprotein. Here we have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor as well as the ability of the drug to compete with a known transported substrate of the protein. We find that ivacaftor stimulates the ATPase activity of the purified protein and can compete with the transport of the fluorescent substrate Hoechst 33342. These findings lead us to conclude that ivacaftor is very likely an efficiently transported substrate of P-glycoprotein. Evidence for state-dependent binding of ivacaftor was obtained using a fluorescent, cysteine-reactive reporter dye. The quiescent, nucleotide-free state in the P-glycoprotein transport cycle appears to bind ivacaftor strongly.
引用
收藏
相关论文
共 50 条
  • [21] ABCB1 genotyping is crucial for treatment with drugs that are P-glycoprotein substrates
    Uhr, M
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 78S - 78S
  • [22] P-glycoprotein ABCB1: a major player in drug handling by mammals
    Borst, Piet
    Schinkel, Alfred H.
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (10): : 4131 - 4133
  • [23] Amyloid-beta induces expression of P-glycoprotein (ABCB1)
    Krohn, M.
    Boehm, M.
    Peters, M.
    Walker, L. C.
    Kroemer, H. K.
    Warzok, R. W.
    Vogelgesang, S.
    ACTA NEUROPATHOLOGICA, 2007, 114 (03) : 316 - 317
  • [24] Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype
    Gurney, H.
    Wong, M.
    Balleine, R. L.
    Rivory, L. P.
    McLachlan, A. J.
    Hoskins, J. M.
    Wilcken, N.
    Clarke, C. L.
    Mann, G. J.
    Collins, M.
    Delforce, S-E
    Lynch, K.
    Schran, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (01) : 33 - 40
  • [25] Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway
    Katayama, Kazuhiro
    Kapoor, Khyati
    Ohnuma, Shinobu
    Patel, Atish
    Swaim, William
    Ambudkar, Indu S.
    Ambudkar, Suresh V.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2015, 1853 (10): : 2361 - 2370
  • [26] Hydrogel-assisted functional reconstitution of human P-glycoprotein (ABCB1) in giant liposomes
    Horger, Kim S.
    Liu, Haiyan
    Rao, Divya K.
    Shulda, Suneet
    Sept, David
    Ambudkar, Suresh V.
    Mayer, Michael
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2015, 1848 (02): : 643 - 653
  • [27] Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms
    Meissner, K
    Jedlitschky, G
    Schwabedissen, HMZ
    Dazert, P
    Eckel, L
    Vogelgesang, S
    Warzok, RW
    Böhm, M
    Lehmann, C
    Wendt, M
    Cascorbi, I
    Kroemer, HK
    PHARMACOGENETICS, 2004, 14 (06): : 381 - 385
  • [28] Effects of Devil's Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein
    Romiti, Nadia
    Tramonti, Gianfranco
    Corti, Alessandro
    Chieli, Elisabetta
    PHYTOMEDICINE, 2009, 16 (12) : 1095 - 1100
  • [29] P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease
    Sita, Giulia
    Hrelia, Patrizia
    Tarozzi, Andrea
    Morroni, Fabiana
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [30] The genetic polymorphisms of ABCB1 decreased the simvastatin efflux function of P-glycoprotein
    Shibakita, Kensuke
    Osabe, Makoto
    Okada, Yusuke
    Yamada, Risako
    Kawai, Shinichi
    Tohkin, Masahiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S186 - S186